

Status: Path 1 of [Dialog Information Services via Modem]

Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 3106900061...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

***** HHHHHHHH SSSSSSSS?

Status: Signing onto Dialog

ENTER PASSWORD:

***** HHHHHHHH SSSSSSSS? *****

Welcome to DIALOG

Status: Connected

Dialog level 00.07.20D

Last logoff: 07oct00 16:35:17

Logon file001 11oct00 12:33:31

*** ANNOUNCEMENT ***

NEW FILE RELEASED

***Prous Science Daily Essentials (Files 458, 459)

***WIPO/PCT Patents Fulltext (File 349)

UPDATING RESUMED

***TFSD Ownership Database (File 540)

***Datamonitor Market Research (File 761)

***Dissertation Abstracts Online (File 35)

RELOADED

***Canadian Business Directory (File 533)

***D&B International Dun's Market Identifiers (File 518)

***D&B European Dun's Market Identifiers (File 521)

***Kompass Canada (File 594)

***WORLD TEXTILES (File 67)

FILES REMOVED

***Thomson Risk Management Database (File 325)

***Sacramento Bee (File 496)

***Kompass UK (File 591)

>>>Get immediate news with Dialog's First Release
news service. First Release updates major newswire
databases within 15 minutes of transmission over the
wire. First Release provides full Dialog searchability
and full-text features. To search First Release files in
OneSearch simply BEGIN FIRST for coverage from Dialog's
broad spectrum of news wires.

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
>>> of new databases, price changes, etc. <<<

KWIC is set to 50.

HILIGHT set on as '*'

File 1:ERIC 1966-2000/Oct 09
(c) format only 2000 The Dialog Corporation

Set Items Description

--- -----

?b 155, 5, 73

11oct00 12:33:45 User259876 Session D126.1

\$0.42 0.120 DialUnits File1

\$0.42 Estimated cost File1

\$0.01 TYMNET
\$0.43 Estimated cost this search
\$0.43 Estimated total session cost 0.120 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2000/Dec W1
(c) format only 2000 Dialog Corporation
File 5:Biosis Previews(R) 1969-2000/Oct W3
(c) 2000 BIOSIS
File 73:EMBASE 1974-2000/Sep W2
(c) 2000 Elsevier Science B.V.

***File 73: Update codes are currently undergoing readjustment.**
For details type Help News73.

Set	Items	Description
---	-----	-----
?s {ocular (w) disease?}		
	132573	OCULAR
	5408352	DISEASE?
S1	3782	(OCULAR (W) DISEASE?)
?s s1 and (gene (w) therapy)		
	3782	S1
	1521525	GENE
	3997432	THERAPY
	39234	GENE(W)THERAPY
S2	44	S1 AND (GENE (W) THERAPY)
?rd		
...completed examining records		
S3	24	RD (unique items)
?s s3 and (lysosomal (w) storage (w) disease)		
	24	S3
	55855	LYSOSOMAL
	186478	STORAGE
	3707364	DISEASE
	1502	LYSOSOMAL(W)STORAGE(W)DISEASE
S4	0	S3 AND (LYSOSOMAL (W) STORAGE (W) DISEASE)
?t s3/3,k/all		

3/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

10533438 20393184

***Gene* *therapy* for *ocular* *disease*.**

Bennett J; Maguire AM
Department of Ophthalmology, Scheie Eye Institute, University of
Pennsylvania, School of Medicine, Philadelphia 19104-6069, USA.
jebennet@mail.med.upenn.edu
Mol Ther (UNITED STATES) Jun 2000, 1 (6) p501-5, ISSN 1525-0016
Journal Code: DRT
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

***Gene* *therapy* for *ocular* *disease*.**

Descriptors: Eye Diseases--Therapy--TH; **Gene* *Therapy*--Methods--MT;
Corneal Diseases--Therapy--TH; Eye Diseases--Genetics--GE; Eye Neoplasms
--Therapy--TH; *Gene* *Therapy*--Trends--TD; Genetic Vectors; Glaucoma
--Therapy--TH; Mutation; Nerve Growth Factors--Genetics--GE; Retinal
Degeneration--Therapy--TH; Retinoblastoma--Therapy--TH; Vitreoretinopathy,
Proliferative--Therapy--TH

3/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

10143257 20008964

Target gene transfer of tissue plasminogen activator to cornea by electric pulse inhibits intracameral fibrin formation and corneal cloudiness.

Sakamoto T; Oshima Y; Nakagawa K; Ishibashi T; Inomata H; Sueishi K
Department of Ophthalmology, Faculty of Medicine, Kyushu University,
Fukuoka, Japan. tsakamot@eye.med.kyushu-u.ac.jp

Human gene therapy (UNITED STATES) Oct 10 1999, 10 (15) p2551-7,
ISSN 1043-0342 Journal Code: A12

Languages: ENGLISH

Document type: JOURNAL ARTICLE

... control eyes and histological damage was not apparent in the treated eyes. This genetic modification allows us to use the corneal endothelium to treat various *ocular* *diseases* and could be a new and effective type of pharmacologic *gene* *therapy*.

3/3,K/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

10100719 98202929

Ability of retroviral transduction to modify the angiogenic characteristics of RPE cells.

Sakamoto T; Spee C; Scuric Z; Gordon EM; Hinton DR; Anderson WF; Ryan SJ
Doheny Eye Institute, Los Angeles, CA 90033, USA.

Graefe's archive for clinical and experimental ophthalmology (GERMANY)
Mar 1998, 236 (3) p220-9, ISSN 0721-832X Journal Code: FPR

Contract/Grant No.: EY01545, EY, NEI; EY03040, EY, NEI

Languages: ENGLISH

Document type: JOURNAL ARTICLE

... undergo long-term changes. CONCLUSIONS: These results suggest that genetically modified RPE cells can be used to modulate ocular angiogenesis and may have potential for *gene* *therapy* of *ocular* *diseases*.

3/3,K/4 (Item 4 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

09902745 99257882

A vitrectomy improves the transfection efficiency of adenoviral vector-mediated gene transfer to Muller cells.

Sakamoto T; Ueno H; Goto Y; Oshima Y; Ishibashi T; Inomata H
Department of Ophthalmology, Faculty of Medicine, Kyushu University,
Fukuoka, Japan.

Gene therapy (ENGLAND) Aug 1998, 5 (8) p1088-97, ISSN 0969-7128
Journal Code: CCE

Languages: ENGLISH

Document type: JOURNAL ARTICLE

The neural retina is a logical target of *gene* *therapy* for various *ocular* *diseases*. We developed a new gene delivery method to the neural retina using an adenoviral vector with a high degree of gene transfection efficiency and less...

Descriptors: Adenoviridae; **Gene* *Therapy*--Methods--MT; *Gene Transfer
; *Genetic Vectors--Administration and Dosage--AD; *Retina; *Retinal
Diseases--Therapy--TH

3/3,K/5 (Item 5 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

09790823 99129201

Targeted gene transfer to corneal endothelium in vivo by electric pulse.

Oshima Y; Sakamoto T; Yamanaka I; Nishi T; Ishibashi T; Inomata H
Department of Ophthalmology, Faculty of Medicine, Kyushu University,
Fukuoka, Japan.

Gene therapy (ENGLAND) Oct 1998, 5 (10) p1347-54, ISSN 0969-7128

Journal Code: CCE

Languages: ENGLISH

Document type: JOURNAL ARTICLE

...highly selective areas of the corneal endothelium without inducing any pathological changes. This targeted gene transfer method appears to have great potential for use in *gene* *therapy* for *ocular* *diseases*.

Descriptors: Electroporation; *Endothelium, Corneal--Metabolism--ME;
*Gene Targeting--Methods--MT; **Gene* *Therapy*--Methods--MT; *Gene Transfer

3/3,K/6 (Item 6 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

09307144 97465002

Ocular *gene* *therapy*: experimental studies and clinical possibilities.

Murata T; Kimura H; Sakamoto T; Osusky R; Spee C; Stout TJ; Hinton DR;
Ryan SJ

Doheny Eye Institute, Los Angeles, CA 90033, USA.

Ophthalmic research (SWITZERLAND) 1997, 29 (5) p242-51, ISSN
0030-3747 Journal Code: OIE

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

Ocular *gene* *therapy*: experimental studies and clinical possibilities.

... diseases. Understanding the genetic basis of human disease will allow for the development of highly specific drugs and for replacement of the altered gene through *gene* *therapy*. *Gene* *therapy* may also be used to introduce a new function into cells with resulting therapeutic benefit. Genes may be delivered into cells in vitro or in...

... vectors. Viral vectors which have been used include retroviruses, adenoviruses, adeno-associated viruses and herpes viruses. Ocular disorders with the greatest potential for benefit of *gene* *therapy* at the current time include hereditary *ocular* *diseases*, including retinitis pigmentosa, tumors such as retinoblastoma or melanoma, and acquired proliferative and neovascular retinal disorders. We have demonstrated the feasibility of ocular *gene* *therapy* in a rabbit model of proliferative vitreoretinopathy, using retroviral vectors containing the herpes simplex virus thymidine kinase 'suicide' gene. Although in vivo transduction efficiency is low, the strong bystander effect results in prominent killing of proliferating cells in this model leading to inhibition of disease. In the future, *gene* *therapy* has the potential for the replacement of defective gene products or introduction of new gene products into ocular cells. The selection of appropriate target genes...

Descriptors: Eye Diseases--Therapy--TH; **Gene* *Therapy*

3/3,K/7 (Item 7 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

09297377 98010129

Perspectives on *gene* *therapy* in the treatment of ocular inflammation.

Nussenblatt RB; Csaky K

National Eye Institute, Bethesda, MD 20892, USA.

Eye (ENGLAND) 1997, 11 (Pt 2) p217-21, ISSN 0950-222X

Journal Code: EYE

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

Perspectives on *gene* *therapy* in the treatment of ocular inflammation.

Gene *therapy* may become a powerful therapeutic strategy. However, the application of this method in the treatment of *ocular* *disease* presents us with interesting and unique questions. *Gene* *therapy* for ocular inflammatory disease has the potential for both therapeutic interventions and a method for studying mechanism of disease. An evolving philosophy on this subject would support the use of somatic *gene* *therapy* for ocular inflammatory disease, even if not life threatening. Major technical questions remain, including the use of the appropriate vector, the best methodology for the...

... variety of proteins can be envisaged for the insertion of genes. The study of gyrate atrophy, an hereditary ocular disorder and an excellent candidate for *gene* *therapy*, has given us enormous information in the development of practical therapeutic strategies, as have in vitro studies of gene insertion. Future concerns will need to...

... on the use of better methods for gene insertion and homologous recombination techniques for the development of animal models and later as a strategy for *gene* *therapy*. The use of *gene* *therapy* as a drug delivery system must also be considered. In addition, the elucidation of the various events controlling transcription for the expression of transgenes in...

Descriptors: Eye Diseases--Therapy--TH; **Gene* *Therapy*--Methods--MT; *Gene Transfer; Apoptosis--Genetics--GE; Autoimmune Diseases--Therapy--TH; Eye Infections--Therapy--TH; Eye Neoplasms--Therapy--TH; *Gene* *Therapy*--Trends--TD; Genetic Vectors; Inflammation--Therapy--TH

3/3,K/8 (Item 8 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

09286894 97443359

Controlled gene gun delivery and expression of DNA within the cornea.

Tanelian DL; Barry MA; Johnston SA; Le T; Smith G

University of Texas Southwestern Medical Center, Dallas, USA.

BioTechniques (UNITED STATES) Sep 1997, 23 (3) p484-8, ISSN 0736-6205

Journal Code: AN3

Languages: ENGLISH

Document type: TECHNICAL REPORT

Selective delivery of genes to ocular tissues in vivo has been a long sought after goal for potential *gene* *therapy* of *ocular* *disease*. The gene gun was considered for this purpose because of its ability to focally transfer DNA to cells through gold microparticles coated with DNA. Through ...

3/3,K/9 (Item 9 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

08782943 96327264

***Gene* *therapy* in ophthalmology]**

Therapie genique en ophtalmologie.

Mashhour B

INSERM U 380, ICGM, Paris.

Bulletin de l'Academie nationale de medecine (FRANCE) Mar 1996, 180

(3) p645-57, ISSN 0001-4079 Journal Code: B8G

Languages: FRENCH Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE ; English Abstract

***Gene* *therapy* in ophthalmology]**

... foreign DNA into a variety of cells including post-mitotic cells, in vivo. They constitute the obligatory targets of gene transfer for a number of *ocular* *diseases* that have been elucidated at the molecular level and are potential targets for *gene* *therapy*. We have therefore analysed the ability of an adenoviral vector to transfer in vivo the E. coli LacZ gene into ocular cells of mice and...

Descriptors: Adenoviruses, Human--Genetics--GE; *Eye Diseases--Therapy--TH; **Gene* *Therapy*; *Genetic Vectors

3/3,K/10 (Item 10 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

08625934 96180085

Molecular biology in ophthalmology. A review of principles and recent advances.

Della NG

Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Md., USA.

Archives of ophthalmology (UNITED STATES) Apr 1996, 114 (4) p457-63, ISSN 0003-9950 Journal Code: 830

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

... phenotype. At the present time, diagnostic tests in ophthalmology for both acquired and inherited diseases are being revolutionized by molecular technology. The molecular genetics of *ocular* *disease* is currently the subject of intense investigation using techniques of gene mapping and isolation. Rapid progress in understanding the molecular basis of eye diseases will advance the treatment of these conditions, including the potential for *gene* *therapy*.

; Amino Acid Sequence; Base Sequence; Eye Diseases--Diagnosis--DI; Eye Diseases--Genetics--GE; *Gene* *Therapy*; Genetics, Biochemical; Molecular Sequence Data

3/3,K/11 (Item 11 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

08567363 97252246

***Gene* *therapy* in *ocular* *disease* [editorial; comment]**

Stout T

Ophthalmology (UNITED STATES) Oct 1995, 102 (10) p1415-6, ISSN 0161-6420 Journal Code: OI5

Comment on Ophthalmology 1995 Oct;102(10):1417-24

Languages: ENGLISH

Document type: COMMENT; EDITORIAL

***Gene* *therapy* in *ocular* *disease* [editorial; comment]**

Descriptors: *Gene* *Therapy*--Methods--MT; *Vitreoretinopathy, Proliferative--Therapy--TH

3/3,K/12 (Item 12 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

08176018 96050930

In vivo adenovirus-mediated gene transfer into ocular tissues.

Mashhour B; Couton D; Perricaudet M; Briand P

CIF 90-03 Institut National de la Sante et de la Recherche Medicale, Institut Cochin de Genetique Moleculaire (ICGM), Paris, France.

Gene therapy (ENGLAND) Mar 1994, 1 (2) p122-6, ISS 969-7128
Journal Code: CCE
Languages: ENGLISH
Document type: JOURNAL ARTICLE

...vivo. In the eyes, most of the cells are quiescent or slowly dividing. They constitute the obligatory targets of gene transfer for a number of *ocular* *diseases* that have been elucidated at the molecular level and are potential targets for *gene* *therapy*. We have therefore analysed the ability of an adenovirus vector to transfer in vivo the Escherichia coli lacZ gene into ocular cells of mice. Injection...

...; beta-Galactosidase--Metabolism--ME; Adenoviridae--Pathogenicity--PY; Cytopathogenic Effect, Viral; Escherichia coli--Genetics--GE; Eye--Anatomy and Histology--AH; Eye Diseases--Therapy--TH; Gene Expression; *Gene* *Therapy*; Gene Transfer--Adverse Effects--AE; Genetic Vectors; Injections; Lac Operon; Mice; Mice, Inbred C57BL; Recombination, Genetic; Time Factors; Vitreous Body

3/3,K/13 (Item 13 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

07923230 94245455

Herpes simplex viral vectors for therapeutic gene delivery to ocular tissues. Recent breakthroughs in the molecular genetics of *ocular* *diseases*.

Pepose JS; Leib DA

Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO 63110.

Investigative ophthalmology & visual science (UNITED STATES) May 1994, 35 (6) p2662-6, ISSN 0146-0404 Journal Code: GWI

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

Herpes simplex viral vectors for therapeutic gene delivery to ocular tissues. Recent breakthroughs in the molecular genetics of *ocular* *diseases*.

Descriptors: Eye Diseases--Therapy--TH; **Gene* *Therapy*--Methods--MT; *Gene Transfer; *Herpesvirus 1, Human--Genetics--GE

3/3,K/14 (Item 14 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

07274215 93135066

Immunogenetic and molecular genetic studies on *ocular* *diseases*]

Ohno S

Department of Ophthalmology, Yokohama City University School of Medicine. Nippon Ganka Gakkai zasshi (JAPAN) Dec 1992, 96 (12) p1558-79, ISSN

0029-0203 Journal Code: 220

Languages: JAPANESE Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE ; English Abstract

Immunogenetic and molecular genetic studies on *ocular* *diseases*]

The immunogenetic mechanisms of various *ocular* *diseases* were investigated utilizing recently developed molecular biological and molecular genetic techniques. It was revealed that HLA-B 51 was closely associated with Behcet's disease...

... s disease and sympathetic ophthalmia, and the immunogenetic mechanism was thought to be similar in both diseases. Recent immunogenetic and molecular genetic investigations on various *ocular* *diseases* have shed new light not only on the genetic individual susceptibility and biased racial differences, but also on the diagnosis of the *ocular* *diseases*,

reclassification of disease entities according to HLA associations, and judgement of disease prognosis. Further progress of molecular medicine may make it possible to treat various intractable *ocular* *diseases* by *gene* *therapy* in the near future.

3/3,K/15 (Item 15 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

07006751 92196713

Gene mapping of *ocular* *diseases*.

Musarella MA

Hospital for Sick Children, Department of Ophthalmology, Toronto, Ontario, Canada.

Survey of ophthalmology (UNITED STATES) Jan-Feb 1992, 36 (4) p285-312, ISSN 0039-6257 Journal Code: VCT

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC

Gene mapping of *ocular* *diseases*.

; Base Sequence; Chromosome Abnormalities--Genetics--GE; Cloning, Molecular--Methods--MT; DNA--Analysis--AN; DNA, Mitochondrial--Genetics--GE; Eye Diseases--Diagnosis--DI; *Gene* *Therapy*; Genome, Human; Linkage (Genetics)--Genetics--GE; Molecular Sequence Data; Pedigree; X Chromosome

3/3,K/16 (Item 1 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

10978550 BIOSIS NO.: 199799599695

Release behavior of poly(lactic acid-co-glycolic acid) implants containing phosphorothioate oligodeoxynucleotide.

AUTHOR: Yamakawa Ichiro(a); Ishida Mari; Kato Takashi; Ando Hidenobu; Asakawa Naoki

AUTHOR ADDRESS: (a)Anal. Chem. Pharm. Res. Div., Tsukuba Res. Lab., Eisai Co. Ltd., 1-3 Tokodai 5-chome, Tsukuba, I**Japan
1997

JOURNAL: Biological & Pharmaceutical Bulletin 20 (4):p455-459 1997

ISSN: 0918-6158

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: intact ODN release in bovine vitreous was found. The implant in the present study may possibly be applicable to intravitreal implantation for the treatment of *ocular* *disease*.

MISCELLANEOUS TERMS: ...*GENE* *THERAPY*;

3/3,K/17 (Item 2 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

10966714 BIOSIS NO.: 199799587859

In vitro antiangiogenic effect of retinoblastoma gene product: Cytostatic *gene* *therapy* strategy for fibrovascular *ocular* *disease*.

AUTHOR: Schwartz S D; Ogueta S B; Lee D A; Farber D B

AUTHOR ADDRESS: Jules Stein Eye Inst., UCLA Sch. Med., Los Angeles, CA**
USA

1997

JOURNAL: Investigative Ophthalmology & Visual Science 38 (4 PART 1-2):p
S787 1997

CONFERENCE/MEETING: Annual Meeting of the Association for Research in Vision and Ophthalmology, Parts 1-2 Fort Lauderdale, Florida, USA May
11-16, 1997

ISSN: 0146-0404
RECORD TYPE: Citation
LANGUAGE: English

In vitro antiangiogenic effect of retinoblastoma gene product: Cytostatic
gene *therapy* strategy for fibrovascular *ocular* *disease*.
MISCELLANEOUS TERMS: ...CYTOSTATIC *GENE* *THERAPY*; ...
...FIBROVASCULAR *OCULAR* *DISEASE*;

3/3,K/18 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.
10645573 BIOSIS NO.: 199699266718
Gene *therapy* for *ocular* *diseases*.
AUTHOR: Sakamoto Taiji
1996
JOURNAL: Rinsho Ganka 50 (9):p1555-1559 1996
ISSN: 0370-5579
DOCUMENT TYPE: Article
RECORD TYPE: Citation
LANGUAGE: Japanese; Non-English
SUMMARY LANGUAGE: Japanese; Non-English
Gene *therapy* for *ocular* *diseases*.
MISCELLANEOUS TERMS: ...*GENE* *THERAPY*; ...
...*OCULAR* *DISEASE*;

3/3,K/19 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.
09838895 BIOSIS NO.: 199598293813
Enhanced angiogenic properties of retinal pigment epithelial cells after
retroviral vector mediated transfer of the urokinase-type plasminogen
activator gene.
AUTHOR: Spee Christine(a); Sakamoto Taiji; Scuric Zorica; Gordon Erlinda M;
Hinton David R; Anderson W French; Ryan Stephen J
AUTHOR ADDRESS: (a)Doheny Eye Inst., USC Sch. Med., Los Angeles, CA*USA
1995
JOURNAL: Journal of Cellular Biochemistry Supplement 0 (21A):p383 1995
CONFERENCE/MEETING: Keystone Symposium on Gene Therapy and Molecular
Medicine Steamboat Springs, Colorado, USA March 26-April 1, 1995
ISSN: 0733-1959
RECORD TYPE: Citation
LANGUAGE: English
MISCELLANEOUS TERMS: ...*GENE* *THERAPY*; ...
...*OCULAR* *DISEASE*;

3/3,K/20 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.
06357172 BIOSIS NO.: 000036060325
TOWARDS *GENE* *THERAPY* FOR INHERITED *OCULAR* *DISEASE* STUDIES OF
RETROVIRALLY MEDIATED HUMAN ADENOSINE DEAMINASE EXPRESSION IN MICE
AUTHOR: MACGREGOR G R; FLETCHER F A; MOORE K A; CHANG S M-W; BELMONT J W;
CASKEY C T
AUTHOR ADDRESS: INST. MOLECULAR GENET., BAYLOR COLL. MED., HOUSTON, TEX.

77030, USA.

JOURNAL: PIATIGORSKY, J., T. SHINOHARA AND P. S. ZELENKA (ED.). UCLA (UNIVERSITY OF CALIFORNIA-LOS ANGELES) SYMPOSIUM ON MOLECULAR AND CELLULAR BIOLOGY NEW SERIES, VOL. 88. MOLECULAR BIOLOGY OF THE EYE: GENES, VISION, AND OCULAR DISEASE; PROCEEDINGS OF A NATIONAL EYE INSTITUTE, SANTA FE, NEW MEXICO, USA. FEBRUARY 6-12, 1988. XXXI+471P. ALAN R. LISS, INC.: NEW YORK, NEW YORK, USA. ILLUS. ISBN 0-8451-2687-3. 0 (0). 1988. 1-22.

CODEN: USMBD

RECORD TYPE: Citation

LANGUAGE: ENGLISH

TOWARDS *GENE* *THERAPY* FOR INHERITED *OCULAR* *DISEASE* STUDIES OF RETROVIRALLY MEDIATED HUMAN ADENOSINE DEAMINASE EXPRESSION IN MICE

3/3,K/21 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2000 Elsevier Science B.V. All rts. reserv.

10672458 EMBASE No: 2000155709

Calcium-binding proteins and their assessment in *ocular* *diseases*

Polans A.S.; Gee R.L.; Walker T.M.; Van Ginkel P.R.

A.S. Polans, Dept. of Ophthalmol./Visual Sciences, Madison Medical School, University of Wisconsin, Madison, WI 53792 United States

Methods in Enzymology (METHODS ENZYMOL.) (United States) 2000, 316/- (103-121)

CODEN: MENZA ISSN: 0076-6879

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH

Calcium-binding proteins and their assessment in *ocular* *diseases*

MEDICAL DESCRIPTORS:

cell division; apoptosis; cell differentiation; neurotransmitter release; phototransduction; immune response; *gene* *therapy*; analytic method; enzyme activity; review; priority journal

3/3,K/22 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2000 Elsevier Science B.V. All rts. reserv.

10635623 EMBASE No: 2000101451

Improvement, not stabilization or slowing the decline of *ocular*

***disease*: The final frontier in treatment**

Azuara-Blanco A.

Dr. A. Azuara-Blanco, Princess Alexandra Eye Pavilion, Chalmers Street, Edinburgh EH3 9HA United Kingdom

Ophthalmology Clinics of North America (OPHTHALMOL. CLIN. NORTH AM.) (United States) 2000, 13/1 (163-166)

CODEN: OCNAF ISSN: 0896-1549

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 43

Improvement, not stabilization or slowing the decline of *ocular*

***disease*: The final frontier in treatment**

Therapeutic strategies aimed to reverse the pathogenic process, replace diseased tissue, and restore visual function represent the final frontier in treatment of chronic *ocular* *disease*. The goal in this approach is improvement, not stabilization or slowing the decline of the disease. Lines of research that can lead to identification of...

MEDICAL DESCRIPTORS:

visual impairment; glaucoma; retina macula age related degeneration; intraocular pressure; visual field defect; optic nerve; blindness; *gene* *therapy*; review; priority journal

3/3,K/23 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.

06894678 EMBASE No: 1997179058

In vitro angiogenesis in *ocular* *diseases*

Sakamoto T.; Ishibashi T.; Inomata H.

Dr. T. Sakamoto, Dept of Ophthalmol, Faculty of Med, Kyushu Univ, 3-1-1

Maidashi, Higashi ku, Fukuoka 812-82 Japan

Folia Ophthalmologica Japonica (FOLIA OPHTHALMOL. JPN.) (Japan) 1997,
48/4 (435-442)

CODEN: NGKYA ISSN: 0015-5667

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: JAPANESE SUMMARY LANGUAGE: ENGLISH; JAPANESE

NUMBER OF REFERENCES: 29

In vitro angiogenesis in *ocular* *diseases*

Angiogenesis in *ocular* *diseases* has been investigated using in vitro
or in vivo methods. Although the results of in vitro studies do not always
reflect the phenomena that occur...

MEDICAL DESCRIPTORS:

cell migration; cell proliferation; choroid; conference paper; endothelium
cell; eye disease; *gene* *therapy*

3/3,K/24 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.

06831515 EMBASE No: 1997114016

Ocular manifestations of genetic and developmental diseases

Hertle R.W.

Dr. R.W. Hertle, Division of Ophthalmology, Children's Hospital of
Philadelphia, 4th and Civic Center Blvd., Philadelphia, PA 19104 United
States

Current Opinion in Ophthalmology (CURR. OPIN. OPHTHALMOL.) (United
States) 1996, 7/6 (72-79)

CODEN: COOTE ISSN: 1040-8738

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 49

...of diagnosis, classification, and therapy in ophthalmology. Tests for
acquired and inherited diseases in ophthalmology are being revolutionized
by biotechnical innovations. The molecular genetics of *ocular* *diseases*
is currently undergoing changes in classification due to intense
investigations using advanced biotechnology. The potential for new
treatment modalities, such as *gene* *therapy*, for molecular eye diseases,
once thought to be pure fiction, is now a reality. This paper will outline
recent changes in classification, organization, and general...

?ds

Set	Items	Description
S1	3782	(OCULAR (W) DISEASE?)
S2	44	S1 AND (GENE (W) THERAPY)
S3	24	RD (unique items)
S4	0	S3 AND (LYSOSOMAL (W) STORAGE (W) DISEASE)

?logoff

11oct00 12:37:45 User259876 Session D126.2

\$1.85 0.578 DialUnits File155

\$3.00 15 Type(s) in Format 3

\$3.00 15 Types

\$4.85 Estimated cost File155

\$2.39 0.4 DialUnits File5
\$8.25 5 Type(s) in Format 3
\$8.25 5 Types
\$10.64 Estimated cost File5
\$7.13 0.839 DialUnits File73
\$9.40 4 Type(s) in Format 3
\$9.40 4 Types
\$16.53 Estimated cost File73
OneSearch, 3 files, 1.842 DialUnits FileOS
\$0.20 TYMNET
\$32.22 Estimated cost this search
\$32.65 Estimated total session cost 1.962 DialUnits

Status: Signed Off. (5 minutes)